Summary of Key Points Core Viewpoint - The financing balance of the Sci-Tech Innovation Board (STAR Market) has increased, indicating a growing interest in investments within this sector, with a total balance of 158.34 billion yuan as of July 1, reflecting a continuous increase over the past seven trading days [1]. Financing Balance - As of July 1, the total financing balance on the STAR Market reached 157.77 billion yuan, an increase of 6.26 million yuan from the previous trading day [1]. - The stock with the highest financing balance is SMIC, with a latest balance of 7.12 billion yuan, followed by Cambrian and Haiguang Information with balances of 4.50 billion yuan and 3.65 billion yuan respectively [1]. - A total of 315 stocks saw an increase in financing balance, while 269 stocks experienced a decrease [1]. - Notable increases in financing balance were observed in Xiangyu Medical (66.24%), Botao Bio (43.29%), and Nanmo Bio (31.08%) [1]. Securities Lending Balance - The total securities lending balance on the STAR Market reached 5.65 billion yuan, with an increase of 8.89 million yuan from the previous trading day [1]. - SMIC also leads in securities lending balance with 20 million yuan, followed by Haiguang Information and Chipone Technology, both at 16 million yuan [2]. - A total of 137 stocks saw an increase in securities lending balance, while 133 stocks experienced a decrease [2]. - Significant increases in securities lending balance were noted for Diao Micro (59.14%), Huahai Qingke (56.71%), and China Shipbuilding Gas (53.60%) [2].

股票代码：688767 证券简称：博拓生物 公告编号：2025-035 杭州博拓生物科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）于2025年5月16日召开2024 年年度股东大会，审议通过了《关于2024年年度利润分配及资本公积转增股本预案的议 案》，权益分派已于2025年6月6日实施完毕。具体内容详见公司于2025年5月30日在上 海证券交易所网站（www.sse.com.cn）披露的《杭州博拓生物科技股份有限公司2024 年年度权益分派实施公告》（公告编号：2025-031）。 公司于2025年6月4日召开2025年第二次临时股东会，审议通过了《关于取消监事会 、增加经营范围并修订 <公司章程> 及修订、新增相关制度的议案》。具体内容详见公司 于2025年5月20日在上海证券交易所网站（www.sse.com.cn）披露的《杭州博拓生物科 技股份有限公司关于取消监事会、增加经营范围并修订 <公司章程> 及修订 ...

股票代码：688767 证券简称：博拓生物 公告编号：2025-035 杭州博拓生物科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）于2025年5月16日召开2024 年年度股东大会，审议通过了《关于2024年年度利润分配及资本公积转增股本预案的议 案》，权益分派已于2025年6月6日实施完毕。具体内容详见公司于2025年5月30日在上 海证券交易所网站（www.sse.com.cn）披露的《杭州博拓生物科技股份有限公司2024 年年度权益分派实施公告》（公告编号：2025-031）。 1 产租赁；园区管理服务；货物进出口；技术进出口；工程和技术研究和试验发展；计算 机软硬件及外围设备制造；信息技术咨询服务；电子真空器件制造；信息安全设备销售； 电子元器件零售；电子真空器件销售；电力电子元器件销售；信息安全设备制造；第二 类医疗设备租赁；计算器设备销售；电力电子元器件制造；电子元器件制造；电子专用 材料制造；集成电路 ...

Group 1 - A total of 24 companies were investigated by institutions on June 25, with 17 companies specifically targeted by funds [1][2] - The most popular company among funds was Botao Bio, which had 21 participating funds, followed by Sanfu Outdoor and Entropy Technology with 7 and 6 funds respectively [1][2] - The companies investigated belong to 12 different industries, with the textile and apparel, and pharmaceutical and biotechnology sectors having the most companies, each with 3 stocks listed [1] Group 2 - Among the companies investigated, 3 had a total market capitalization exceeding 50 billion yuan, while 13 had a market cap below 10 billion yuan [1] - In terms of market performance, 9 stocks among the investigated companies saw an increase in the last 5 days, with Haike Xinyuan, Bai'ao Intelligent, and Ganfeng Lithium leading with increases of 50.83%, 10.42%, and 5.88% respectively [1][2] - Conversely, 8 stocks experienced declines, with Mankalon, Botao Bio, and China Merchants Energy showing the largest drops of 7.94%, 5.35%, and 4.76% respectively [1][2]

博拓生物 20250617 摘要 博拓生物通过入股脑机接口公司清创视界，占比 5%，旨在实现从诊断 到诊疗一体化的战略转型，该公司基于浙江大学的技术成果，专注于抑 郁症方向的脑机接口研发。 国家对脑机接口技术高度重视，已将其列为科技飞跃重点领域，并推出 2030 发展规划，总预算超 300 亿，未来几年仍有 168 亿投入，同时中 国正出台百亿级重大脑疾病规划，政策支持驱动国内新兴公司发展。 脑机接口技术分为侵入式和非侵入式，侵入式信号质量高，可达 1-5 万 赫兹，能解析神经元信号，但有创；非侵入式无创但信号质量差。目前 主要应用于康复领域，如手指运动恢复、疲劳和睡眠监测，侵入式在运 动重建和重大脑疾病治疗有应用。 国内脑机接口研究集中在高校和科研机构，如清华、浙大等，企业层面 有智然、星岛等公司走在前沿。国际上正出台统一标准，国内逐渐跟进。 医疗领域，美国 FDA 对 DBS 有明确标准，但感知觉恢复和运动康复尚 无具体标准。 Q&A 博拓生物在脑机接口领域的投资背景和布局情况是什么？ 博拓生物主要在 IVD 领域深耕了十多年，聚焦于 POCT 的研发、生产和销售。 其产品布局涵盖五大系列：毒品检测、传染 ...

Group 1 - The company held its second extraordinary general meeting of shareholders on June 4, 2025, to elect the fourth board of directors, which includes three non-independent directors and three independent directors, along with one employee representative director [1][2] - The newly elected board of directors will serve a term of three years starting from the date of the meeting [1] - Chen Yinlong was elected as the chairman of the fourth board of directors, and various specialized committees were established, including the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee [2] Group 2 - The company appointed Wu Shujing as the general manager and Chen Yujie, Ye Chunsheng, and Liu Chao as vice general managers, with Fei Qijun appointed as the vice general manager and board secretary, and Yu Miaomiao as the financial officer [3][4] - All appointed senior management personnel meet the qualifications required for their positions and comply with relevant laws and regulations [4][7] - Huang Yufeng was appointed as the securities affairs representative to assist the board secretary [3][4] Group 3 - The third board of directors' independent director Wang Wenming and non-independent director Gao Hongmei will no longer serve after the completion of the board transition [5] - The company will no longer have a supervisory board, and its functions will be assumed by the audit committee of the board of directors [5]

Meeting Details - The shareholders' meeting of Hangzhou Botao Biological Technology Co., Ltd. was held on June 4, 2025 [1] - The meeting took place at a designated location in Hangzhou [1] - A total of 43 ordinary shareholders attended, holding 49,053,096 voting rights, which represents 45.9872% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved, with 99.9035% of votes in favor, 0.0877% abstaining, and 0.0088% against [1] - The cumulative voting results included the election of Chen Yinlong, Chen Yujie, and Wu Shujian as non-independent directors, with their respective votes confirming their election [2] Independent Directors Election - Wang Liang and Duan Jianping were elected as independent directors of the fourth board [2] - The voting for these independent directors also met the required thresholds for approval [2] Legal Compliance - The meeting's convening and proceedings were confirmed to comply with legal and regulatory requirements, ensuring the legitimacy of the participants and voting processes [3]

Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and validity of the procedures and results of the second extraordinary general meeting of shareholders for Hangzhou Botao Biotechnology Co., Ltd. in 2025 [1][11]. Group 1: Meeting Procedures - The meeting was convened following the approval of the board of directors on May 19, 2025, and the notice was published on May 20, 2025, on the Shanghai Stock Exchange and other platforms [2][3]. - The meeting is scheduled for June 4, 2025, at 14:00, with specific voting times for online participation [3]. Group 2: Agenda and Voting - The agenda includes proposals to cancel the supervisory board, expand the business scope, amend the company’s articles of association, and elect new board members [2][4]. - A total of 43 shareholders (or their proxies) attended the meeting, representing 49,053,096 voting shares, which is 45.9872% of the total voting shares [5]. Group 3: Voting Results - All proposed resolutions were approved by the shareholders, with significant support for each item, such as 99.9035% approval for the proposal to amend the articles of association [6][10]. - The election of non-independent and independent directors received unanimous support, with no votes against any of the candidates [8][9].

证券代码：688767 证券简称：博拓生物 公告编号：2025-033 杭州博拓生物科技股份有限公司 第四届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）第四届董事会第一次 会议于 2025 年 6 月 4 日在公司会议室以现场结合通讯方式召开，经全体董事一 致同意，豁免本次会议通知时间的要求。本次会议与会董事共同推举陈音龙先生 主持，应出席董事 7 人，实际出席董事 7 人，高级管理人员列席了会议。本次会 议的召集、召开符合《中华人民共和国公司法》等法律、法规和《公司章程》的 有关规定。与会董事通过认真讨论，形成决议如下： 一、审议通过了《关于选举公司第四届董事会董事长的议案》 同意选举陈音龙先生为公司第四届董事会董事长，任期与本届董事会任期一 致。 表决结果：7 票同意，0 票反对，0 票弃权。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的公 司《关于完成董事会换届选举及聘任高级管理人员、证券事务代表的公告》。 ...

股票代码：688767 证券简称：博拓生物 公告编号：2025-034 杭州博拓生物科技股份有限公司 关于完成董事会换届选举及聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"或"博拓生物"）于2025年6 月4日召开2025年第二次临时股东会，选举产生的第四届董事会成员，与公司于2025 年5月19日召开的职工代表大会选举的职工代表董事共同组成第四届董事会。同日，公 司召开第四届董事会第一次会议，审议通过了选举公司董事长、各专门委员会委员、 聘任第四届高级管理人员和证券事务代表等相关议案。现将具体情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 5 月 19 日，公司召开职工代表大会选举叶春生先生为公司第四届董事会职 工代表董事。2025 年 6 月 4 日，公司召开 2025 年第二次临时股东会，审议通过了《关 于董事会换届选举暨选举第四届董事会非独立董事的议案》《关于董事会换届选举暨选 举第四届董事会独立董事的 ...